Major cancer treatment trial using cannabis about to get underway

629 0

Althea is involved in a massive study to explore treating cancer with cannabis

The Australian Centre for Cannabinoid Clinical and Research Excellence (CARE NSW) is about to start a trial period for cancer treatment with the help of a new source, Althea Group Holdings. Last Wednesday it was announced by Althea an agreement to be the supplier of medical cannabis in the New South Wales area. Two different cannabis medicines will be supplied by Althea specifically for the trial; however, the deal did not include a certain amount (minimum or maximum) to be purchased.

Based on the press release from a few days ago, Althea will be part of the list of several suppliers that provide medicines to CARE NSW and the number of patients participating in the study will be up to 600. The center, with the help of the University of Newcastle, will be processing the medicine on commercial terms.

The CEO of Althea, Josh Fegan, said during a press release, “Althea is proud to be one of the companies supplying cannabis medicines to the Australian Centre for Cannabinoid Clinical and Research Excellence clinical trial. We are big believers in the potential benefits of medicinal cannabis and pleased to support an initiative such as this, which will further our scientific understanding of its use in areas of unmet needs. We look forward to the results of the CARE NSW Trial.”

Althea is an Australian-based company that counts on a license to produce, supply and export cannabis-related products that are in the form of medicines that meet the pharmaceutical level standards. Althea, which is listed publicly on the Australian Securities Exchange, is heavily involved in related aspects surrounding the cannabis matter such as education, access to the products, management services, among others. Those eligible patients can count on Althea to help them understand the process that involves the treatment of a certain condition with medical cannabis.